MedTrace Logo

Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

NCT00128063 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2007-04-24

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily intravenous (i.v.) doses. The secondary objectives are to evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.

Conditions

  • HIV Infections

Interventions

DRUG

succinylated human serum albumin

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • Prothya Biosolutions

    collaborator INDUSTRY

  • International Antiviral Therapy Evaluation Center

    lead OTHER

Principal Investigators

  • Joep MA Lange, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Jan Prins, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2006-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128063 on ClinicalTrials.gov